From DCAT Value Chain Insights (VCI)
Moderna Therapeutics has Melissa J. Moore, PhD, chief scientific officer (CSO) of Moderna’s mRNA research platform. Responsible for leading all mRNA biology research at Moderna, Dr. Moore will play a critical leadership role as the company enters a new growth phase. Dr. Moore will assume her new role at Moderna as of October 3, 2016.
Currently a member of Moderna’s scientific advisory board, Dr. Moore joins the company from the University of Massachusetts Medical School (UMMS), where she is currently professor of biochemistry and molecular pharmacology, Eleanor Eustis Farrington chair in cancer research and investigator at the Howard Hughes Medical Institute (HHMI). In addition, Dr. Moore was a founding co-director of the RNA Therapeutics Institute (RTI) at UMMS. Upon joining Moderna, Dr. Moore will resign from HHMI, but retain her academic affiliation with UMMS as a part-time faculty member.
Source: Moderna Therapeutics
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription